Sponsored by
A new study suggests that postoperative gabapentin, a neuromodulator usually taken for nerve pain, may improve overall survival in patients with newly diagnosed glioblastoma. Across two cohorts totaling 1,072 patients, those who received gabapentin lived a median of 4 months longer at Mass General Brigham and 6 months longer at UCSF compared to those who did not. Gabapentin targets TSP-1, a synaptogenic protein implicated in tumor progression. Importantly, the study findings showed that gabapentin use was associated with reduced serum TSP-1 levels. The study has limitations, including a retrospective design and variability in dosing across patients, but hopefully future prospective trials confirm these results and explore optimal dosing.